J&J Well Positioned For US Drug Pricing Changes Regardless Of Timing Or Form, Duato Says
Executive Summary
Boasting of 14 current or near-term blockbusters and success staving off Remicade biosimilars, Johnson & Johnson says its growth derives 100% from sales volume, not price increases. All the same, it continues call for slow pricing reform.
You may also be interested in...
Pfizer's Epogen Biosimilar Retacrit Launches At 33% Off In A US Market Where Amgen's Already Competitive
Retacrit – a biosimilar of Amgen's Epogen and J&J's Procrit – will launch at aggressive discounts to the original anemia products in a market where Amgen's already proven there's a tough fight for market share.
Pfizer's Epogen Biosimilar Retacrit Launches At 33% Off In A US Market Where Amgen's Already Competitive
Retacrit – a biosimilar of Amgen's Epogen and J&J's Procrit – will launch at aggressive discounts to the original anemia products in a market where Amgen's already proven there's a tough fight for market share.
J&J Pharma Growth Led By Oncology; Firm Tries To Assuage Zytiga Concerns
The pharmaceutical business continues to withstand the arrival of more Remicade biosimilars and the firm maintains it will have solid growth even with generic competition to its Zytiga.